Pharma Audits Your CMO Has a GMP Certificate. Here’s Why That’s Not Enough for Your Next MHRA Inspection Read More » July 16, 2026 No Comments
Risk-Based Audits Generic Drug Companies and Signal Detection: Why You Can’t Copy Your Originator’s PV System Read More » July 14, 2026 No Comments
Risk-Based Audits The Hidden Cost of Repeat Inspection Findings – and How to Break the Cycle Read More » July 9, 2026 No Comments
Pharmacovigilance Services Five Indian Pharma Companies Got FDA Warning Letters in Q1 2026 for the Same Mistake: Here’s the Pattern Read More » July 7, 2026 No Comments
Risk-Based Audits Import Alert 66-40 Explained: How One Data Integrity Finding Can Block Your Entire Supply Chain for 18 Months Read More » July 2, 2026 No Comments
Risk-Based Audits The FDA Just Issued Its First Warning Letter for AI Misuse in CGMP Documentation: Here’s What Happened Read More » June 30, 2026 No Comments
GVP Audits GDP Compliance for Cold Chain Logistics: Updated Requirements and Audit Checklist Read More » June 25, 2026 No Comments
Pharmacovigilance Services The New EU Pharmaceutical Legislation 2026: What Changes for Pharmacovigilance? Read More » June 23, 2026 No Comments
Pharma Audits FDA Draft Guidance on Responding to Form 483 Observations: A Practical Guide for CGMP Sites Read More » June 18, 2026 No Comments
Pharmacovigilance Services FDA’s New Overseas Inspection Approach: What Pharma Sites Need to Know Read More » June 16, 2026 No Comments